Treatment of Obesity-Related Complications with Novel Classes of Naturally Occurring PPAR Agonists

Bassaganya-Riera, Josep; Guri, Amir J.; Hontecillas, Raquel

Treatment of Obesity-Related Complications with Novel Classes of Naturally Occurring PPAR Agonists

dc.contributor.author	Bassaganya-Riera, Josep	en
dc.contributor.author	Guri, Amir J.	en
dc.contributor.author	Hontecillas, Raquel	en
dc.date.accessioned	2017-09-18T09:51:51Z	en
dc.date.available	2017-09-18T09:51:51Z	en
dc.date.issued	2010-12-28	en
dc.date.updated	2017-09-18T09:51:51Z	en
dc.description.abstract	The prevalence of obesity and its associated comorbidities has grown to epidemic proportions in the US and worldwide. Thus, developing safe and effective therapeutic approaches against these widespread and debilitating diseases is important and timely. Activation of peroxisome proliferator-activated receptors (PPARs) α, γ, and δ through several classes of pharmaceuticals can prevent or treat a variety of metabolic and inflammatory diseases, including type II diabetes (T2D). Thus, PPARs represent important molecular targets for developing novel and better treatments for a wide range of debilitating and widespread obesity-related diseases and disorders. However, available PPAR γ agonistic drugs such as Avandia have significant adverse side effects, including weight gain, fluid retention, hepatotoxicity, and congestive heart failure. An alternative to synthetic agonists of PPAR γ is the discovery and development of naturally occurring and safer nutraceuticals that may be dual or pan PPAR agonists. The purpose of this paper is to summarize the health effects of three plant-derived PPAR agonists: abscisic acid (ABA), punicic acid (PUA), and catalpic acid (CAA) in the prevention and treatment of chronic inflammatory and metabolic diseases and disorders.	en
dc.description.version	Published version	en
dc.format.mimetype	application/pdf	en
dc.identifier.citation	Josep Bassaganya-Riera, Amir J. Guri, and Raquel Hontecillas, “Treatment of Obesity-Related Complications with Novel Classes of Naturally Occurring PPAR Agonists,” Journal of Obesity, vol. 2011, Article ID 897894, 7 pages, 2011. doi:10.1155/2011/897894	en
dc.identifier.doi	https://doi.org/10.1155/2011/897894	en
dc.identifier.uri	http://hdl.handle.net/10919/79019	en
dc.language.iso	en	en
dc.publisher	Hindawi	en
dc.rights	Creative Commons Attribution 4.0 International	en
dc.rights.holder	Copyright © 2011 Josep Bassaganya-Riera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.	en
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/	en
dc.title	Treatment of Obesity-Related Complications with Novel Classes of Naturally Occurring PPAR Agonists	en
dc.title.serial	Journal of Obesity	en
dc.type	Article - Refereed	en
dc.type.dcmitype	Text	en